SEARCH

Current Edition

Crohn's disease

Theravance to lay off 75% of employees alongside larger restructuring

The restructuring at Theravance comes just weeks after one of the company’s more closely watched drugs failed a key test. Called izencitinib, the drug is …

Continue Reading →